American Society of Hematology

Figure 5.

$Figure 5. T cell-anergy did not account for the differential peripheral SAg reactivity. Vβ7CD4 T cells from responders and weak responders were activated with the polyclonal T-cell mitogen PHA (top row), with vector (A20 V, middle row), or with HERV-K18 SAg–transfected A20 cells (bottom row). Cell cycle analysis of Vβ7+CD4+ T cells was performed with 7-actinomycin D (7-AAD). The lower fraction of cells entering the cell cycle in the expander could reflect a regulatory mechanism encountered among samples with high proportions of SAg-reactive T cells, which was previously recognized for MMTV SAgs. Horizontal bars and percentages refer to the fraction of cells in Go1, and S+2M, respectively.$

T cell-anergy did not account for the differential peripheral SAg reactivity. Vβ7CD4 T cells from responders and weak responders were activated with the polyclonal T-cell mitogen PHA (top row), with vector (A20 V, middle row), or with HERV-K18 SAg–transfected A20 cells (bottom row). Cell cycle analysis of Vβ7⁺CD4⁺ T cells was performed with 7-actinomycin D (7-AAD). The lower fraction of cells entering the cell cycle in the expander could reflect a regulatory mechanism encountered among samples with high proportions of SAg-reactive T cells, which was previously recognized for MMTV SAgs. Horizontal bars and percentages refer to the fraction of cells in G_o1, and S+₂M, respectively.

This Feature Is Available To Subscribers Only